| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target...
 
																	Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of PF...
 
																	
 
																	
 
																	
 
																	Cardiff Oncology Inc. (NASDAQ: CRDF) plummeted 22.96% in its stock value on Tuesday, following a disappointing second quarter e...
